In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Celyad (CYAD – Research Report), with a price target of $37.00. The company’s shares closed last Monday at $12.47.
According to TipRanks.com, White is a top 100 analyst with an average return of 31.8% and a 54.4% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and TRACON Pharmaceuticals.
Currently, the analyst consensus on Celyad is a Strong Buy with an average price target of $27.33, which is a 130.6% upside from current levels. In a report issued on May 29, William Blair also maintained a Buy rating on the stock.
The company has a one-year high of $20.42 and a one-year low of $4.10. Currently, Celyad has an average volume of 16.63K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Celyad SA is a clinical-stage biopharmaceutical company, which engages in the development of cell-based therapies for the treatment of cancer. It operates through the following segments: Cardiology, Immuno-oncology, and Corporate. The Cardiology segment includes the company’s Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.